Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 1.00 |
| ▸ | RXRB | P28702 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TPMT | P51580 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.54 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.54 |
| ▸ | BAD | Q92934 | 1/20 | 0.54 |
| ▸ | RXRG | P48443 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2041424 | 0.84 | TSHR (0.85) | RXRARXRBTSHRALOX15SRD5A2 | |
| SCHEMBL15521764 | 0.84 | EGFR (0.72) | RXRARXRBTSHREGFRSRD5A2 | |
| SCHEMBL30610360 | 0.84 | EGFR (0.72) | RXRARXRBTSHREGFRSRD5A2 | |
| SCHEMBL18687046 | 0.84 | EGFR (0.72) | RXRARXRBTSHREGFRSRD5A2 | |
| SCHEMBL142861 | 0.84 | EGFR (0.72) | RXRARXRBTSHREGFRSRD5A2 | |
| SCHEMBL23202431 | 0.84 | EGFR (0.72) | RXRARXRBTSHREGFRSRD5A2 | |
| SCHEMBL22734016 | 0.84 | EGFR (0.72) | RXRARXRBTSHREGFRSRD5A2 | |
| SCHEMBL21133280 | 0.84 | EGFR (0.72) | RXRARXRBTSHREGFRSRD5A2 | |
| SCHEMBL21133337 | 0.84 | EGFR (0.72) | RXRARXRBTSHREGFRSRD5A2 | |
| SCHEMBL864660 | 0.84 | EGFR (0.72) | RXRARXRBTSHREGFRSRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117050524-A | Wear-resistant amphiphobic polyphenylene sulfide composite material and preparation method thereof | 江西聚真科技发展有限公司 | 2023-11-14 | — | — | CN | claimed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| WO-2021068950-A1 | AMIDE COMPOUND AND MEDICAL USE THEREOF AS STING INHIBITOR | 中国药科大学 | 2021-04-15 | — | — | WO | disclosed |
| US-20140134753-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140134753-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-05-15 | — | — | US | disclosed |
| US-8653119-B2 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653119-B2 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-02-18 | — | — | US | disclosed |
| EP-1436249-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-1608617-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-03-15 | — | — | US | disclosed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| US-20060178438-A1 | Muscarinic agonists | ELI LILLY AND COMPANY (IN) | 2006-08-10 | — | — | US | disclosed |
| US-20060154922-A1 | Muscarinic agonists | ELILILLY AND COMPANY (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| EP-1140072-B1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2004-04-14 | — | — | EP | disclosed |
| WO-2004010943-A2 | SUBSTITUTED BENZANILIDES AS MODULATORS OF THE CCR5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1140072-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1140072-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040239-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154922-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | RXRA 617/4885RXRB 521/4885TSHR 112/4885 |
| US-20060178438-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | RXRA 617/4885RXRB 521/4885TSHR 112/4885 |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | TTR, TTPA, PRNP | RXRA 3616/4885RXRB 3630/4885TSHR 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.